Petros Pharmaceuticals (PTPI) Institutional Ownership $0.03 -0.01 (-13.59%) As of 05/27/2025 03:54 PM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Petros Pharmaceuticals (NASDAQ:PTPI)CurrentInstitutional OwnershipPercentage12.34%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$973.61KNumber ofInstitutional Sellers(last 12 months)0 Get PTPI Insider Trade Alerts Want to know when executives and insiders are buying or selling Petros Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data PTPI Institutional Buying and Selling by Quarter Petros Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2025 Jane Street Group LLC563,594$39K0.0%N/A26.324% 8/2/2023 Bank of Montreal Can10,000$27K0.0%N/A0.478% 1/27/2022Emfo LLC10,000$33K0.0%-64.3%0.048% 11/12/2021 NorthRock Partners LLC115,295$431K0.0%-47.4%1.173% 9/17/2021 Virtu Financial LLC14,364$45K0.0%N/A0.146% 8/16/2021 Shay Capital LLC238,764$747K0.1%-7.0%2.437% 8/13/2021 Renaissance Technologies LLC54,887$172K0.0%-70.4%0.560% 8/13/2021 Geode Capital Management LLC23,725$74K0.0%+67.3%0.242% 8/13/2021 Vanguard Group Inc.107,500$336K0.0%+21.2%1.097% 8/12/2021 NorthRock Partners LLC219,188$686K0.1%-35.1%2.237% 8/10/2021 CM Management LLC100,000$313K0.2%+122.2%1.021% 8/5/2021 Platform Technology Partners44,000$138K0.1%N/A0.449% 5/21/2021 Citadel Advisors LLC35,492$131K0.0%N/A0.362% 5/18/2021 Citadel Advisors LLC35,492$131K0.0%N/A0.363% 5/13/2021 Renaissance Technologies LLC185,545$692K0.0%+29.5%1.900% 5/12/2021 Geode Capital Management LLC14,180$52K0.0%N/A0.145% 5/11/2021 NorthRock Partners LLC337,531$1.26M0.1%-12.3%3.455% 5/7/2021BlackRock Inc.18,277$68K0.0%+35.1%0.187% (Data available from 1/1/2016 forward) PTPI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PTPI shares? During the previous two years, the following institutional investors and hedge funds held shares of Petros Pharmaceuticals shares: Jane Street Group LLC ($39K), Bank of Montreal Can ($27K).Learn more on PTPI's institutional investors. What percentage of Petros Pharmaceuticals stock is owned by institutional investors? 12.34% of Petros Pharmaceuticals stock is owned by institutional investors. Learn more on PTPI's institutional investor holdings. Which institutional investors have been buying Petros Pharmaceuticals stock? The following institutional investors have purchased Petros Pharmaceuticals stock in the last 24 months: Jane Street Group LLC ($563.59K), and Bank of Montreal Can ($10K). How much institutional buying is happening at Petros Pharmaceuticals? Institutional investors have bought a total of 573,594 shares in the last 24 months. This purchase volume represents approximately $1.48M in transactions. Related Companies Dermata Therapeutics Institutional Ownership Onconetix Institutional Ownership Alaunos Therapeutics Institutional Ownership IM Cannabis Institutional Ownership Mustang Bio Institutional Ownership Matinas Biopharma Institutional Ownership Clearmind Medicine Institutional Ownership CERo Therapeutics Institutional Ownership Galecto Institutional Ownership PainReform Institutional Ownership This page (NASDAQ:PTPI) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
